Sriram Venkataraman - Jan 27, 2023 Form 4 Insider Report for RVL Pharmaceuticals plc (RVLP)

Signature
By: /s/ Sriram Venkataraman
Stock symbol
RVLP
Transactions as of
Jan 27, 2023
Transactions value $
$0
Form type
4
Date filed
1/30/2023, 04:28 PM
Previous filing
Aug 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVLP Ordinary Shares Other $0 -1.03M -100% $0.00* 0 Jan 27, 2023 By Avista Capital investment fund F1, F2
holding RVLP Ordinary Shares 23.7M Jan 27, 2023 By Avista Capital investment fund F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares distributed in kind by Orbit Co-Invest III LLC ("Orbit III") to its members, on a pro rata basis, for no consideration.
F2 Represents shares of the Issuer held by Orbit III. Avista Capital Partners III GP, L.P. ("ACP GP") is the manager of Orbit III. Mr. Venkataraman is a member of the investment committee of ACP GP. By virtue of this relationship, Mr. Venkataraman may be deemed to have shared voting and investment power with respect to the shares held by Orbit III. Mr. Venkataraman disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
F3 Represents shares of the Issuer held by Avista Healthcare Partners, L.P. ("AHP"). Avista Healthcare Partners GP, Ltd. ("AHP GP") is the general partner of AHP. Mr. Venkataraman is a member of the investment committee of AHP GP. By virtue of this relationship, Mr. Venkataraman may be deemed to share voting and investment power with respect to the shares held by AHP. Mr. Venkataraman disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.